Access to Medicine Index mentioned in an article on Patent systems

In the article titled ‘Teure Medikamente erhöhen den Druck’, guest columnist Simon Schmid writes about pricing, patents and licencing and their inteconnectedness in the pharmaceutical industry.

The article mentions increased transparency in patent portfolios of AstraZeneca, Merck and Novo Nordisk as an example and how this move not only is of interest to public health but also brings helps the company ranking in the Access to Medicine Index.